Sidney Kimmel Cancer Center at Thomas Jefferson University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

Phase 2

Completed

Conditions: Non-Hodgkin's Lymphoma
Plasma Cell Myeloma

Interventions: Procedure: Hematopoietic Cell Transplantation
Drug: Tbo-filgrastim
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-10-23

Last Posted Date: 2022-11-17

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 76

Registration Number: NCT03317899

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Contrast-Enhanced Ultrasound Imaging in Diagnosing Liver Cancer in Patients With Cirrhosis

Not Applicable

Completed

Conditions: Liver Cirrhosis

Interventions: Procedure: Dynamic Contrast-Enhanced Ultrasound Imaging

First Posted Date: 2017-10-23

Last Posted Date: 2022-11-17

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 612

Registration Number: NCT03318380

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
Albert Einstein Medical Center, Philadelphia, Pennsylvania, United States

and more 8 locations

Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization of Adnexal Masses in Patients Undergoing Surgery

Early Phase 1

Completed

Conditions: Adnexal Mass

Interventions: Drug: Perflutren Lipid Microspheres
Procedure: Contrast-Enhanced Subharmonic Ultrasound Imaging

First Posted Date: 2017-09-29

Last Posted Date: 2024-03-12

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 12

Registration Number: NCT03297112

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides

Phase 2

Withdrawn

Conditions: Mycosis Fungoides

Interventions: Drug: Mechlorethamine Hydrochloride Gel
Procedure: Total Skin Electron Beam Radiation Therapy

First Posted Date: 2017-09-20

Last Posted Date: 2018-01-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT03288818

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

Not Applicable

Recruiting

Conditions: WHO Grade II Glioma
Glioblastoma
WHO Grade III Glioma

Interventions: Radiation: Intensity-Modulated Radiation Therapy
Other: Quality-of-Life

First Posted Date: 2017-08-16

Last Posted Date: 2024-03-13

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 125

Registration Number: NCT03251027

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Window of Opportunity Trial of Nivolumab and Tadalafil in Patients With Squamous Cell Carcinoma of the Head and Neck

Early Phase 1

Completed

Conditions: Lip, Oral Cavity and Pharynx
Larynx

Interventions: Biological: Nivolumab
Procedure: Therapeutic Conventional Surgery
Drug: Tadalafil

First Posted Date: 2017-08-03

Last Posted Date: 2022-10-05

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 50

Registration Number: NCT03238365

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors

Not Applicable

Completed

Conditions: Stage I Uterine Corpus Cancer
Stage IA Cervical Cancer
Stage II Uterine Corpus Cancer
Stage III Uterine Corpus Cancer
Stage IIIA Cervical Cancer
Stage IIIB Ovarian Cancer
Stage I Breast Cancer
Stage I Cervical Cancer
Stage I Ovarian Cancer
Stage IA Ovarian Cancer

Interventions: Other: Informational Intervention

First Posted Date: 2017-06-26

Last Posted Date: 2018-02-22

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 40

Registration Number: NCT03198286

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States
🇺🇸
Reading Hospital, Reading, Pennsylvania, United States

Educational Intervention in Increasing Knowledge About Prostate Cancer in High-Risk Neighborhoods

Not Applicable

Conditions: Prostate

Interventions: Other: Educational Intervention

First Posted Date: 2017-06-23

Last Posted Date: 2020-01-18

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 296

Registration Number: NCT03197896

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Electronic Patient Reported Outcomes in Measuring Health-Related Quality of Life in Patients With Stage I-IV Prostate Cancer Undergoing Treatment

Terminated

Conditions: Prostate

Interventions: Other: Internet-Based Intervention

First Posted Date: 2017-06-23

Last Posted Date: 2018-06-12

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 20

Registration Number: NCT03197948

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas

Phase 2

Recruiting

Conditions: Ann Arbor Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma
Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma
Non-Hodgkin's Lymphoma
Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Ann Arbor Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Ann Arbor Stage II Follicular Lymphoma
Ann Arbor Stage II Nodal Marginal Zone Lymphoma
Ann Abor Stage III B-Cell Non-Hodgkin Lymphoma

Interventions: Drug: Ibrutinib
Biological: Obinutuzumab
Other: Laboratory Biomarker Analysis

First Posted Date: 2017-06-23

Last Posted Date: 2024-04-22

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 30

Registration Number: NCT03198026

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy